Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4099130
Max Phase: Preclinical
Molecular Formula: C28H35N6NaO10S
Molecular Weight: 648.69
Molecule Type: Small molecule
Associated Items:
ID: ALA4099130
Max Phase: Preclinical
Molecular Formula: C28H35N6NaO10S
Molecular Weight: 648.69
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CNS(N)(=O)=O)O[C@@](OCCCn2cc(-c3ccc(-c4ccccc4)cc3)nn2)(C(=O)[O-])C[C@@H]1O.[Na+]
Standard InChI: InChI=1S/C28H36N6O10S.Na/c1-17(35)31-24-22(36)14-28(27(39)40,44-26(24)25(38)23(37)15-30-45(29,41)42)43-13-5-12-34-16-21(32-33-34)20-10-8-19(9-11-20)18-6-3-2-4-7-18;/h2-4,6-11,16,22-26,30,36-38H,5,12-15H2,1H3,(H,31,35)(H,39,40)(H2,29,41,42);/q;+1/p-1/t22-,23+,24+,25+,26+,28+;/m0./s1
Standard InChI Key: SBXABUGNUSCAEA-GWDSEHCUSA-M
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 648.69 | Molecular Weight (Monoisotopic): 648.2214 | AlogP: -1.03 | #Rotatable Bonds: 14 |
Polar Surface Area: 248.45 | Molecular Species: ACID | HBA: 12 | HBD: 7 |
#RO5 Violations: 3 | HBA (Lipinski): 16 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 2.87 | CX Basic pKa: | CX LogP: -0.58 | CX LogD: -4.07 |
Aromatic Rings: 3 | Heavy Atoms: 45 | QED Weighted: 0.10 | Np Likeness Score: -0.26 |
1. Prescher H, Frank M, Gütgemann S, Kuhfeldt E, Schweizer A, Nitschke L, Watzl C, Brossmer R.. (2017) Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune Evasion., 60 (3): [PMID:28103033] [10.1021/acs.jmedchem.6b01111] |
Source(1):